Islet Cell Transplantion: Update on Current Clinical Trials

Abstract In the last 15 years, clinical islet transplantation has made the leap from experimental procedure to standard of care for a highly selective group of patients. Due to a risk/benefit calculation involving the required systemic immunosuppression, the procedure is only considered in patients with type 1 diabetes, complicated by severe hypoglycemia or end stage renal disease. In this review, we summarize current outcomes of the procedure and take a look at ongoing and future improvements and refinements of beta cell therapy.
Source: Current Transplantation Reports - Category: Transplant Surgery Source Type: research